In vitro response of primary human bone marrow stromal cells to recombinant human bone morphogenic protein-2 in the early and late stages of osteoblast differentiation by Kim, I S et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
In vitro response of primary human bone marrow stromal cells to
recombinant human bone morphogenic protein-2 in the early and
late stages of osteoblast differentiation
Kim, I S; Song, Y M; Cho, T H; Park, Y D; Lee, K B; Noh, I; Weber, F E; Hwang, S J
Kim, I S; Song, Y M; Cho, T H; Park, Y D; Lee, K B; Noh, I; Weber, F E; Hwang, S J (2008). In vitro response of
primary human bone marrow stromal cells to recombinant human bone morphogenic protein-2 in the early and late
stages of osteoblast differentiation. Development, Growth and Differentiation, 50(7):553-564.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Development, Growth and Differentiation 2008, 50(7):553-564.
Kim, I S; Song, Y M; Cho, T H; Park, Y D; Lee, K B; Noh, I; Weber, F E; Hwang, S J (2008). In vitro response of
primary human bone marrow stromal cells to recombinant human bone morphogenic protein-2 in the early and late
stages of osteoblast differentiation. Development, Growth and Differentiation, 50(7):553-564.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Development, Growth and Differentiation 2008, 50(7):553-564.
In vitro response of primary human bone marrow stromal cells to
recombinant human bone morphogenic protein-2 in the early and
late stages of osteoblast differentiation
Abstract
A number of factors must be added to human bone marrow stromal cells (hBMSCs) in vitro to induce
osteogenesis, including ascorbic acid (AA), beta-glycerophosphate (GP), and dexamethasone (Dex).
Bone morphogenic protein (BMP)-2 is an osteoinductive factor that can commit stromal cells to
differentiate into osteoblasts. However, it is still not clear whether the addition of BMP-2 alone in vitro
can induce hBMSCs to complete osteoblast differentiation, resulting in matrix mineralization. This
study compares the effects of BMP-2 and Dex, alone and combined, on the early and late stages of
hBMSC differentiation. We found that BMP-2 causes a significant induction of alkaline phosphatase
(ALP) activity in hBMSCs, with a transcriptional upregulation of known BMP-2-responsive genes, and
the stable expression of cbfa1 in the nucleus and the regions surrounding the nucleus in the early phase
of osteoblast differentiation. However, continuous treatment with BMP-2 alone at doses ranging from
100 to 300 ng/mL results in a less efficient enhancement of in vitro matrix mineralization, despite a
significant induction of ALP activity at a concentration of 100 ng/mL. Our results reflect how the effects
of BMP-2 on hBMSCs can vary depending on the stage of osteoblast differentiation, and highlight the
need to understand the role of BMP-2 in primary hBMSCs derived from diverse sources in order to
increase the efficiency of using BMP-2 in osteoinductive therapies.
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Abstract 
A number of factors must be added to human bone marrow stromal cells (hBMSCs) in 
vitro to induce osteogenesis, including ascordic acid (AA), -glycerophosphate (GP), 
and dexamethasone (Dex). Bone morphogenic protein (BMP)-2 is an osteoinductive 
factor that can commit stromal cells to differentiate into osteoblasts . However, it is still 
not clear whether the addition of BMP-2 alone in vitro can induce hBMSCs to complete 
osteoblast differentiation, resulting in matrix mineralization. This study compares the 
effects of BMP-2 and Dex, alone and combined, on the early and late stages of hBMSC 
differentiation. We found that BMP-2 causes a significant induction of alkaline 
phosphatase (ALP) activity in hBMSCs, with a transcriptional up-regulation of known 
BMP-2-responsive genes, and the stable expression of cbfa1 in the nucleus and the 
regions surrounding the nucleus in the early phase of osteoblast differentiation. 
However, continuous treatment with BMP-2 alone at doses ranging from 100-300 ng/ml 
results in a less efficient enhancement of in vitro matrix mineralization, despite a 
significant induction of ALP activity at a concentration of 100 ng/ml. Our results reflect 
how the effects of BMP-2 on hBMSCs can vary depending on the stage of osteoblast 
differentiation, and highlight the need to understand the role of BMP-2 in primary 
hBMSCs derived from diverse sources in order to increase the efficiency of using BMP-
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2 in osteoinductive therapies.  
Key words: alkaline phosphatase, bone morphogenic protein-2, human bone marrow 
stromal cells, in vitro matrix mineralization, osteoblast differentiation  
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Introduction 
BMPs constitute a unique group of proteins within the TGF- superfamily of 
genes, and play critical roles in the regulation of bone metabolism and embryonic 
development (Hogan, 1996). It is well known that BMP signaling plays an important 
role in skeletal development through both intramembraneous and endochondral 
ossification (Kingsley, 1994). It has been suggested by Cheng et al. that BMP-2, BMP-6, 
and BMP-9 possess the most potent osteogenic activity in mesenchymal stem cells 
(Cheng et al., 2003). Recombinant forms of BMPs, particularly, BMP-2 and BMP-7, 
have been shown to have the ability to heal critical-sized bone defects in animals when 
combined with suitable scaffolds (Chen et al., 2002, Vogelin et al., 2005). Furthermore, 
due to its commercial availability, recombinant human (rh) BMP-2 has been 
increasingly used in various clinical therapeutic trials in the dental and orthopedic fields, 
such as in bone regeneration associated with dental implants, spinal fusion, and 
nonunion of skeletons (Bragdon et al., 2003, Wikesjo et al., 2005, Gautschi et al., 2007).  
 
The cellular function and signaling pathway of BMP-2 in osteoblast differentiation 
are currently being investigated and are not fully understood in human cells. The BMPs 
have been shown to be efficacious in the differentiation BMSCs into osteoblasts and 
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chondrocytes in rodents, dogs, and humans (Wozney et al., 1988, Chen et al., 2004). 
When cells are exposed to BMP-2, several signaling pathways, including the Smad and 
mitogen-activated protein kinase (MAPK) pathways, are activated to induce osteogenic 
activity (Fujii et al., 1999, Lai & Cheng, 2002). BMP-2 signaling also induces the 
Wnt/-catenin signaling pathway, which is considered critical for bone mass regulation 
(Mbalaviele et al., 2005, Chen et al., 2007). This multiple cross-talk of signaling 
pathways suggests that rhBMP2 could potentially be used for bone anabolic therapies.  
 
Adult adherent mesenchymal stem cells (MSCs) derived from bone marrow can be 
differentiated into osteoblasts in relatively simple conditions compared with other cell 
lineages (Pittenger et al., 1999). After the confluent monolayer plating of cells, 
supplementation of the medium with AA, -GP, and Dex can induce osteoblast 
differentiation of MSCs with a change in morphology, elevation of ALP activity, and 
acceleration of matrix mineralization (Cheng et al., 1994). Dex has contrasting dual 
functions in bone metabolism; it is a prerequisite supplement for osteoblast 
differentiation and at the same time it is a catabolic factor inducing bone loss or 
osteoporosis with prolonged administration in a human system (Canalis & Delany, 2002, 
Canalis et al., 2002). Differentiation from stem cells to a functional osteoblast involves 
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a series of different stages, and is mainly controlled by the specific transcription factor, 
cbfa1 (Ducy et al., 1997, Ducy et al., 2000). The sequential and stage-specific 
expression of osteoblast marker genes characterizes osteogenesis. ALP and type I 
collagen (ColI) are expressed in the early phase of osteogenesis, followed by the 
expression of osteopontin (OPN) and bone sialoprotein (BSP). Finally, the only truly 
osteoblast-specific gene, osteocalcin (OC), is produced during the mineralization period 
(zur Nieden et al., 2003). The expression of these osteoblast-related markers is 
regulated by cbfa1, which is a major target gene of BMP-2 signaling (Harada et al.,
1999, Rawadi et al., 2003).  
 
Despite the great therapeutic importance of BMP-2, there are only a few in vitro 
studies of primary stromal cells derived from human bone marrow. Moreover, in 
contrast to the obvious osteogenic effects seen in the in vitro analysis of BMSCs 
derived from mice or rats, there is controversy regarding the effects of BMP-2 alone on 
ALP activity or matrix mineralization based on in vitro studies of the osteogenic 
differentiation of primary hBMSCs  (Diefenderfer et al., 2003b, Osyczka et al., 2004). 
One group reported that BMP-2 treatment induced a strong osteogenic effect in 
hBMSCs, as demonstrated by an increase in ALP activity and the enhanced deposition 
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of mineral, similar to what was seen in mouse and rat BMSCs (Lecanda et al., 1997). 
However, other groups have shown insensitivity to BMP-2 in hBMSCs, marked by low 
ALP activity and weak in vitro mineralization (Diefenderfer et al., 2003a, Jorgensen et 
al., 2004). In vitro studies are valuable for defining the responses of individual primary 
hBMSCs to BMP-2, and are therefore necessary for guiding preclinical studies or 
clinical use. Recent in vitro studies on the osteogenic potential of BMP-2 in human stem 
cells have been conducted with a co-treatment of dexamethasone (Dex), rather than with 
BMP-2 alone, even though Dex is considered to be catabolic to bone tissue. Thus, we 
evaluated the in vitro effect of BMP-2 in primary hBMSCs (n=16) isolated from iliac 
crest-derived bone marrow, with a focus on the characterization of the cellular response 
in the early and late phases of differentiation. In this experimental report, we 
investigated the osteogenesis of hBMSCs by treating cells with either BMP-2 or Dex, or 
a combination of BMP-2 and Dex, and assessing ALP activity, gene expression of 
osteoblast-related markers using real time RT-PCR, osteocalcin expression, and in vitro 
matrix mineralization. 
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MATERIALS & METHODS 
 
Materials 
Carrier-free rhBMP-2 and goat polyclonal anti-human Cbfa1/Runx2 specific 
antibody were purchased from R&D Systems (Minneapolis, MN, U.S.A.). The ALP 
assay kit and staining kit were obtained from Sigma-Aldrich (St. Louis, U.S.A.). Dex, 
AA, and - GP were purchased from Sigma Chemical Co. (St. Louis, U.S.A.). Ficoll-
paque plus was obtained from Amersham Biosciences (Uppsala, Sweden). Fetal bovine 
serum (FBS), Phosphate Buffered Saline (PBS, pH 7.4), penicillin/streptomycin, and 
trypsin were purchased from GIBCO BRL (Grand Island, NY, U.S.A.). SuperScriptTM 
reverse transcriptase kit and TRIzol reagent were obtained from Invitrogen (Carlsbad, 
CA, U.S.A.). SYBR Green PCR-mix for real-time RT-PCR was obtained from Applied 
Biosystems (CA, U.S.A.). Low- and high-glucose Dulbecco’s Modified Eagle’s 
Medium (DMEM) was purchased from GIBCO BRL or JBI (Daegu, South Korea). The 
Cell Counting Kit (CCK)-8 using WST-8 was obtained from Dojindo Laboratories 
(Tokyo, Japan). FITC-conjugated human specific anti-CD105 (Endoglin) and anti-CD45 
antibody was purchased from Ancell Co. (Bayport, MN, U.S.A.), anti-CD90 (Tyr-1) 
antibody from BD Biosciences (San Jose, CA, U.S.A), anti-mouse IgG from R&D 
Systems (Minneapolis, MN, U.S.A.). The BTI Intact Osteocalcin EIA kit was purchased 
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from Biomedical Technologies Inc. (Stoughton, MA, U.S.A.).  
 
Preparation and culture of hBMSCs 
Bone marrow was obtained from the iliac crest of 16 donors (7 males and 9 
females, ranging in age from 18 to 55 years). All participants were informed about the 
harvesting of bone marrow before surgery. The harvesting of bone marrow was 
performed only on subjects who gave consent, and this study was approved by the local 
ethics committee (IRB at Seoul National University Dental Hospital, Nr: CRI05008) 
according to the legal regulations for human tissue and organs in Korea. hBMSCs were 
cultured according to the protocol described by Caterson et al., 2002. The marrow 
suspension was collected in a syringe containing 6,000 U/ml Heparin and was mixed 
with PBS solution in the same volume ratio and centrifuged at 2,500 rpm for 10 min. 
After aspiration of the upper PBS layer, the marrow suspension was layered on Ficoll-
paque (1:5 ratio) and centrifuged at 2,580 rpm for 30 min. The nucleated cells 
concentrated at the interface were collected and washed with PBS. Adherent cells were 
plated at a density of 2 x 106 cells/100 mm culture plate and cultured in an expansion 
medium containing low-glucose DMEM, 100 units/ml penicillin, 100 Lg/ml 
streptomycin, and 10% heat inactivated FBS (HIFBS) under a humidified atmosphere of 
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5% CO2 at 37°C. The medium was changed every three or four days. Cells were 
passaged when they reached 70% confluence, and second passage cells were used for 
the present experiments. Osteogenic studies were performed by plating at a cell density 
of 1.7 x 104 cells/cm2 in a differentiation medium supplemented with high-glucose 
DMEM, 10% HIFBS, AA (50 µg/ml), and -GP (10 mM). Dex (10 nM), rhBMP-2 
(100-300 ng/ml), or a combination of Dex and rhBMP-2 were added at 1 or 2 days post-
plating, when the cells were confluent, and were replenished at the time of medium 
change, every 3 or 4 days. To confirm the potential of multi-differentiation into 
adipocytes or chondrocytes, hBMSCs were cultured at a cell density of 1.7 x 104
cells/cm2 in adipogenic differentiation medium supplemented with 50 µM 3-isobutyl-1-
methylxanthine, 60 nM indomethasin and 5 µg/ml insulin for 20 days or cultured as 
high-density pellets for 21 days in chondrogenic differentiation medium supplemented 
with 1 % Insulin-transferrin-selenium (ITS), 1 mM sodium pyruvate and 50 µM L-
proline (Noth et al., 2002). Media change was done every 3 days. 
 
Fluorescence-activated cell sorting (FACS) 
A total of 105 cells of the first passaged hBMSCs was washed with PBS and 
suspended in washing buffer (PBS buffer containing 0.1% paraformaldehyde (Sigma) 
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and 1% BSA) for FACS analysis. Then, cells were incubated with FITC-conjugated 
anti-human CD105 (Endoglin), anti-human CD90, anti-human CD45 antibody and 
mouse IgG (negative control) for 30 min - 1 hr in the dark after washing with washing 
buffer (PBS buffer containing 1% BSA). The stained cells and non-treated cells were 
sorted by BD FACSAria Cell Sorting System (BD Biosciences, USA). 
 
ALP activity assay  
ALP activities were determined by measuring the amount of -nitrophenol 
produced using -nitrophenol phosphate substrate. Cell lysates were mixed with 
alkaline buffer solution and gently shaken for 10 min. ALP substrate was added at RT 
for 30 min. After stopping the reaction with the addition of 0.05N NaOH, the 
absorbance at 405 nm was read and compared to a standard curve prepared with -
nitrophenol standard solution. Enzyme activity was normalized to the protein 
concentration of the cell layer, which was measured using the Bio-Rad protein assay 
(Bio-Rad, Hercules, CA, USA). 
 
Quantitative real-time RT-PCR 
Total RNA was extracted by adding 0.5 ml of TRizol reagent. Each 1 µg RNA was 
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subjected to cDNA synthesis with SuperScriptTM Reverse Transcriptase II and oligo12-18 
primers. SYBR® Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) 
was used to detect the accumulation of PCR product during cycling with the ABI Prism 
7700 sequence Detection system (Applied Biosystems, CA). The thermocycling 
conditions were pre-denaturation at 95°C for 10 min, amplification using three-step 
cycles of denaturation at 95°C for 15 s, annealing and extension at 60°C for 1 min, a 
duration of 30 cycles, with a final dissociation cycle at 95°C for 15 s, 60°C for 1 min, 
and 95°C for 15 s. Human-specific oligonucleotide primers for real-time RT-PCR were 
designed with product sizes less than 200 bp using Real-Time PCR system Sequence 
Detection Software v 1.3 (Applied Biosystems, CA, USA). The human primer 
sequences were as follows: -actin (Genbank# BC004251) forward-
ATTGCCGACAGGATGCAG, reverse-TTGCTGATCCACATCTGCTGG; ALP 
(Genbank# AH005272) forward-ACCATGAAGGAAAAGCCAAGC, reverse- 
CCACCAAATGTGAAGACGTGG; Osteopontin (Genbank# J04765) forward-
TTGAATGGTGCATACAAGGCC, reverse-AATCTGGACTGCTTGTGGCTG; 
Osteocalcin (Genbank# X51699) forward-CAAAGGTGCAGCCTTTGTGTC, reverse- 
AACTCGTCACAGTCCGGATTG; IGF-1 (Genbank# M27544)  forward-
TGGTGGATGCTCTTCAGTTCG, reverse-TTAGATCACAGCTCCGGAAGC; 
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Osterix (Genbank# AF477981) forward-CAAGGTGTATGGCAAGGCTTC, reverse- 
AGCTCATCCGAACGAGTGAAC; Dlx5 (Genbank# BC006226) forward- 
TACCCAGCCAAAGCTTATGCC, reverse-CCATTCACCATTCTCACCTCG; Cbfa1 
(Genbank# NM_004348) forward-TATGGCACTTCGTCAGGATCC, reverse- 
GCGTCAACACCATCATTCTGG.  
Histochemical staining 
After fixation in citrate-acetone solution and rinsing, the activity of the plasma 
membrane-associated ALP was detected using an ALP Leukocyte Staining Kit, 
according to the manufacturerዊ�s protocol. Adipocytes were detected by Oil Red O, 
which stains lipid droplets in the cytoplasm (Pittenger et al., 1999). To analyze 
chondrogenic differentiation, high-density pellets were washed once with phosphate-
buffered saline (PBS), embedded in Tissue-Tek® O.C.T (Sakura Finetek U.S.A.,Inc., 
Torrance, CA), and frozen in liquid nitrogen. Cryosections at 20 µm thickness were 
mounted on slides and air dried overnight. The sections were stained with stained with 
0.1% Toluidine blue for 1min for a proteoglycan-rich extracellular matrix as described 
by Song et al., 2004.
Evaluation of mineralization; Alizarin red & von Kossa staining 
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(1) Alizarin red S staining: Calcium deposition was determined using Alizarin red 
S staining. hBMSCs were cultured in 24 wells for 21 days with continuous treatment 
with each compound. Cells were fixed in 70% ice-cold ethanol for 1 h, rinsed with 
double distilled H2O, and then stained with 40 mM alizarin red S at pH 4.2 for 10 min 
with gentle agitation. After five repeated washings with double distilled H2O, the cells 
were rinsed for 15 min with 1x PBS with gentle agitation.  
(2) von Kossa staining: Cells were cultured for 28 days under the same conditions 
as those of the Alizarin red S staining. Then, the cells were washed with PBS, fixed in 
10% formaldehyde solution for 10 min, and washed in deionized water. The fixed cells 
were incubated with 5% silver nitrate solution for 30 min in darkness and rinsed in 
deionized water. The cells were treated with sodium-carbonate formaldehyde solution 
for 2 min, and then incubated with staining solution (5% sodium thiosulphate) for 20 
min after rinsing in deionized water. Finally, the cells were washed again in deionized 
water and left to air dry.  
 
Immunofluorescence staining 
hBMSCs were plated at a cell density of 3,000 cells/coverslide in the normal 
growth medium. The next day, cells were pre-treated in serum-free DMEM for two 
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hours and then treated with Dex (10 nM) or rhBMP-2 (100 ng/ml). At 2 and 24 hours 
after treatment, cells were washed three times with PBS, fixed in 10% formaldehyde for 
10 min, and blocked in a solution of 30% PBS-buffered bovine serum albumin (BSA) 
for 30 min. Cells were incubated with anti-Cbfa1 antibody (1:150) for 2 hours at room 
temperature, washed twice with PBS, followed by incubation with the secondary 
antibody labeled with Cy3 mouse anti-goat IgG (1:100) for 40 min. Primary antibody 
controls were processed in parallel using only the second antibody. Slides were washed 
in PBS for 15 min and incubat d with PBS-buffered 4’, 6-diamino-2-phenyindole 
(DAPI) solution (1 µg/µl, Santa Cruz Biotechnology) with a dilution ratio of 1:1000 for 
nucleus staining. Images of stained cells were captured using Olympus Fluoview FV300 
Confocal Laser Scanning Microcscope and Fluoview software (Olympus optical Co. 
LTD, Tokyo, Japan). 
Enzyme-linked immunosorbent assay (ELISA) 
After 21 days of culture, particulates were removed from cell culture supernatants 
by centrifugation or defreezing, and the supernatants were added into 96-well ELISA 
plates. The OC levels in culture supernatants were measured with the BTI Intact OC 
EIA kit (Biomedical Technologies inc. USA). Subsequent to incubation, aspiration and 
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washing, OC conjugate (100 µl/well) was added as per the manufacturer's instructions. 
Standards for OC (1-50 ng/ml) were run in each series. The optical density of each well 
was determined within 30 min using a microplate reader set to a 450-nm wavelength 
correction for optical imperfections in the plate. The ELISA was repeated in triplicate 
with two independent samples (n=3). 
 
Statistical analysis 
Treatment groups within experiments were performed in triplicate, and all values 
are expressed as the mean ± standard error of the mean. Student's t-test was used to 
evaluate differences between the two groups. All analyses were statistically analyzed 
using the SigmaPlot (version 8.0) statistical analysis software program. A p value < 
0.05 was considered statistically significant. 
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Results 
The cultured hBMSCs appeared as a single cell on 3 days post-plating. It took 
about 10 or 12 days until adherent fibroblastic cells formed colonies. The cell showed 
the typical spindle-like, long and elongated fibroblastic shape (Fig. 1A). To confirm 
homogeneity of the hBMSCs isolated by the above mentioned isolation procedure, flow 
cytometry to the surface marker of the stem cell, CD105 (Endoglin), CD90 as positive 
markers, and CD45 as a negative stem cell marker, was performed with the first 
passaged hBMSCs (Vogel et al., 2003). The cell surfaces (n=5-6, different donors) were 
positive for mesenchymal stem cell marker, the CD105 (92.3±1.5 %) and CD90 
(95.8±2.1 %) and negative for marker of hematopoietic origin, CD45 (2±1.1 %) (Fig. 
1B). Cells were cultured in low-glucose DMEM, 10% (v/v) HIFBS, for maintenance 
where hBMSCs showed stable viability. hBMSCs cultured in this study could be 
differentiated into adipocytes or chondrocytes in each specific differentiation medium 
(Fig.1C).  
 
Cell morphology and proliferation 
 
Treatment with Dex (Dex alone or combination of Dex with rhBMP-2) caused a 
morphological transformation of the cells from a long spindle-like shape to a cuboidal-
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like shape. However, BMP-treated cells maintain a fibroblastic shape (Fig.2A). Cell 
proliferation was assessed in 7-day cultures that had been continuously treated with 
each of the supplements (Fig. 2B). All tested hBMSCs (n=4) showed the same tendency 
with each supplement. Treatment with rhBMP-2 (100 ng/ml) alone did not have an 
effect on the proliferation of hBMSCs, but treatment with Dex alone (10nM) and co-
treatment with Dex and BMP-2 significantly decreased proliferation to 70% of that 
observed in the control (p<0.05).  
 
rhBMP-2 response in the early phase of osteoblast differentiation of hBMSCs 
 
The authors assessed the ALP activity in each sample as a representative index of 
osteoblast differentiation at 7 days after culture with each treatment (Zernik et al., 1990)
(Fig. 3). Each specimen showed different levels of ALP activity, even under the control 
condition, probably due to the individual cell properties or the heterogeneity of the 
population of BMSCs, which may include osteoprogenitor cells in addition to 
undifferentiated stem cells (Owen & Friedenstein, 1988). However, all tested hBMSCs, 
with the exception of one sample in each treatment, responded to rhBMP-2 (100ng/ml) 
or Dex (10 nM) with a significant elevation of ALP activity that ranged from 1.6- to 28-
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fold over the control value. ALP staining of cells on 24-well culture plates after 12 days 
of culture matched the levels of ALP activity (Fig. 3A). There was a significant 
synergistic effect with the combined treatment of Dex and rhBMP-2 over Dex or 
rhBMP-2 alone in the same sample. In an analysis of ALP activity between male (n=7) 
and female (n=9) cells, the fold increase for each condition (Dex, BMP-2 or Dex/BMP-
2) over the control in the male group was 2 -3 fold higher than that in the female group, 
but the difference was not significant (Fig. 3B). Additionally, we analyzed the 
correlation between the age of donors and the osteogenic capacity of the hBMSCs. Cells 
cultured from individuals under 20 years old (n=6) responded more effectively to the 
treatment of Dex, BMP-2, or Dex/BMP-2 than cells from individuals between the ages 
of 20 and 35 (n=8) or over the age of 40 years old (n=2). Because of the high variability 
between donors from the same group and the relatively small numbers within each 
group, we could not observe the significance in the gender- and age-specific differences 
(Fig. 3C).  
 
We examined the transcriptional expression of several osteoblast-related genes on 
days 3 and 7 after supplement treatment and in more than three independent and 
randomly chosen samples (Fig. 4). Quantitative real-time RT-PCR of ALP, osterix, IGF-
Page 20 of 46Development Growth and Differentiation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
ዊ�ዊ�
ዊ�ዊ�
1 showed a significant induction after treatment with rhBMP-2, or the combined 
treatment with Dex and rhBMP-2. OPN mRNA expression was significantly induced by 
rhBMP-2 treatment and inhibited by Dex treatment at 7 days. However, rhBMP-2 
treatment did not affect the mRNA expression of ColI or OC, the latter of which was 
significantly decreased in the presence of Dex at day 7 (Fig. 4A). The BMP-2–
responsive transcriptional factors, cbfa1, osterix, and dlx5 (Gersbach et al., 2004, Ryoo 
et al., 2006) showed differential transcriptional expression. There was no rhBMP-2-
mediated up-regulation of cbfa1 and dlx5 mRNA expression at days 3 or 7, but rhBMP-
2 treatment induced a significant and time-dependent increase in osterix mRNA 
expression (Fig. 4B).  
The expression or cellular localization of Cbfa1 after treatment with rhBMP-2 
Cbfa1 was observed by immunofluorescence at 2 and 24 hrs after treatment with 
either Dex or rhBMP-2 treatment alone (Fig. 5). Directly following a 2-hour rhBMP-2 
treatment and for the subsequent 24 hours, Cbfa1 was localized either to the area 
surrounding the nucleus or inside the nucleus. In contrast to the pattern observed in 
rhBMP-2-treated cells, Cbfa1 expression was weak in the cytoplasm of most of cells at 
2 hours and then drastically decreased at 24 hours in non-treated control conditions (Fig. 
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5A). In the presence of Dex, Cbfa1 was mainly localized to the area surrounding the 
nucleus, and this expression pattern was maintained for 24 hrs, at which point the 
expression became relatively hazy. The percentage of cbfa1-positive cells was 
significantly higher in rhBMP-2 treated cells compared to control cells or Dex-treated 
cells at 24 hrs, and the percentage of cbfa1-positive cells dropped between 2 hrs to 24 
hrs in non-treated control culture (Fig. 5B). Although there was a slightly different 
pattern of Cbfa1 expression between donors, we consistently observed that rhBMP-2-
treatment induced the stabilization of Cbfa1 expression or modulated the cellular 
localization of Cbfa1 near the nucleus. Our analyses suggest that cbfa1 expression is 
stabilized by rhBMP-2 in hBMSCs, even though we could not demonstrate a 
transcriptional induction of cbfa1 mediated by rhBMP-2 at an earlier time point prior to 
day 3 or 7.  
 
Responses of hBMSCs to rhBMP-2 in the late stage of differentiation  
In our analyses of the effect of rhBMP-2 in the late stage of differentiation, we 
obtained results that contradicted our expectation that rhBMP-2 would stimulate 
terminal differentiation. Real-time RT-PCR of OC, a late bone marker, did not reveal an 
increase of OC mRNA in cells supplemented with Dex or rhBMP-2 at the early time 
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point (day 7), but did reveal an induction of OC mRNA in VtD-treated cells. The OC 
secretion levels measured at day 21 were consistent with RT-PCR findings (Fig.6A). 
Deposition of calcified extracellular matrix was observed by Alizarin red S staining at 
day 21 or von kossa staining at day 28 (Fig. 6B, C). In contrast to the osteoinductive 
effect of rhBMP-2 in the early stage of osteoblast differentiation, there was no 
corresponding effect observed for late-stage mineral deposition. In the von Kossa 
staining of 5 samples of randomly chosen hBMSCs, while some hBMSCs (Sample 1 
and 5) showed the formation of a few mineralized nodules, we found that rhBMP-2 
treatment was typically inefficient in inducing matrix mineralization, regardless of the 
dose, which ranged from 100 ng/ml to 300 ng/ml. Dex-treated cells produced densely 
mineralized regions and the combined treatment of Dex with rhBMP-2 produced a 
synergistic effect on matrix mineralization. Sample 3 was the only hBMSC line that 
showed no induction of ALP activity after Dex-treatment, which probably led to failed 
mineralization. With Alizarin red S staining, we saw small plaques of calcified 
extracellular matrix histologically, especially in Dex-treated cells, but we observed only 
minimal staining in the control or rhBMP-2 (100ng/ml) alone-treated group.  
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Discussion 
 
This study focused on the characterization of the in vitro responses of primary 
hBMSCs to rhBMP-2 treatment. The results of our study confirm that the responses to 
rhBMP-2 in the early stage of differentiation are normal as measured by the detection of 
elevated ALP activity, transcriptional induction of BMP-responsive genes (osteopontin, 
IGF-1, and osterix) and nuclear localization of Cbfa1 (Fujita et al., 2001, Diefenderfer 
et al., 2003a, Gersbach et al., 2004). However, we found that the effect of rhBMP-2 
treatment on in vitro matrix mineralization was generally weak, independently of the 
treatment dose range (100–300 ng/ml), and the effects of rhBMP-2 varied slightly 
between individual cell lines. Our results differ from those of previous studies that 
demonstrated an increase in nodule formation of human stromal cell line after treatment 
with rhBMP-2, probably because previous experiments were typically done in the 
presence of Dex. We are unable to explain why the BMP-2-mediated osteoinductive 
responses of hBMSCs in the early stage of differentiation do not correlate with matrix 
mineralization in the late phase of differentiation. A better understanding of the 
molecular mechanisms of osteogenesis in hBMSCs is necessary to address this issue.  
 
The findings in this study raise questions about how ALP activity in the early stage 
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of osteogenesis is related to in vitro matrix mineralization. The current belief is that 
matrix mineralization is initiated by the expression of ALP (Zernik et al., 1990). This is 
supported by the report of Wennberg et al., which demonstrates that osteoblasts derived 
from tissue nonspecific ALP knockout mice differentiate normally, but are unable to 
initiate mineralization in vitro (Wennberg et al., 2000). However, different results have 
been reported in human cells. In osteoblast differentiation using commercial hBMSCs 
from a single donor, rhBMP alone could not to induce in vitro matrix mineralization, 
despite a significant induction of the ALP gene. However, matrix mineralization was 
stimulated with either the combined treatment of rhBMP-2 and IGF-1 or Dex (Koch et 
al., 2005). Recently, Kurata et al. reported that the formation of extracellular calcium 
was not enhanced, although the manipulated overexpression of osterix increased the 
transcriptional expression of ALP and osteopontin in human fetal mesenchymal stem 
cells (Kurata et al., 2007). These results, which are in agreement with our findings, 
suggest that the increase in ALP expression at an early differentiation stage may not 
necessarily translate into the enhanced terminal differentiation of human cells.  
 
Another discrepancy is the insensitivity of OC mRNA expression in response to 
rhBMP-2 treatment. OC, a late bone marker, signals terminal osteoblast differentiation 
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(zur Nieden et al., 2003). The OC promoter is regulated by cbfa1 and is activated in 
rodent cells by treatment with rhBMP-2 (Alliston et al., 2001, Huang et al., 2002). In 
the present study, neither Dex nor rhBMP-2 affected OC mRNA production, in contrast 
with a 2-fold induction observed in VtD-treated cells. Similar results have been reported 
by Jorgensen et al. (Jorgensen et al., 2004), and this may also reflect a difference in the 
response to rhBMP-2 or Dex between human and rodent cells. It is possible that 
unknown factors or conditions, aside from the elevation of ALP activity or the increase 
of OC, are necessary for matrix mineralization in human cells.  
 
A recent report by the authors had demonstrated that hBMSCs isolated by the same 
method as that in the present study could enhance bone formation in the rat calvarial 
defect model (Kim et al., 2007). The application of hBMSCs in hyaluronan-based 
hydrogels led to an increase in both bone formation and endothelial cells. In vivo,
hBMSCs or hBMSCs treated with rhBMP-2 successfully form bone without treatment 
by Dex. This discrepancy between in vivo and in vitro tests might be explained by the 
fact that endogenous stress hormones have similar functions (Udelsman et al., 1986, 
Leopold et al., 2003), and may play roles in bone mineralization. Despite some 
differences in the response of hBMSCs to rhBMP-2, the findings in this study are useful 
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for the osteogenic analysis of new substances, which have been implicated in human 
bone metabolism or in primary hBMSCs derived from diverse sources, in an effort to 
improve the efficacies of osteoinductive therapies.  
 
In conclusion, the present study shows that hBMSCs respond differently to 
rhBMP-2 in the early and late differentiation stages, and that rhBMP-2 alone is 
insufficient for the induction of in vitro matrix mineralization in hBMSCs. This weak 
effect of rhBMP-2 on in vitro matrix mineralization may not accurately represent the 
situation in vivo. However, the diverse responses of primary hBMSCs to rhBMP-2 
treatment may reflect the variability of outcomes with BMP-2 therapy. These results 
highlight the need for further in vitro studies of the molecular mechanism responsible 
for matrix mineralization.  
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Figure legends 
Figure 1.  Characterization and multilineage differentiation of hBMSCs. (A) Stromal 
cells were cultured after Ficoll density gradient fractionation. A single cell appeared at 
days 2–4 and formed fibroblastic colonies at days 10–12 after the first plating. (B) 
Homogeneity of the isolation procedure was demonstrated by FACS. Data shown were 
obtained from hBMSCs at first passage using FITC-conjugated antihuman CD105, 
human CD90 antibody as positive stem cell marker, and human CD45 antibody as 
negative marker. (C) Isolated hBMSCs were tested for the ability to differentiate in 
vitro to multiple lineages. Cultured cells were each shown to differentiate appropriately 
to the adipogenic (Adipo), chondrogenic (Chondro), and osteogenic (Osteo) lineages. 
Adipogenesis was indicated by the accumulation of neutral lipid vacuoles that stain with 
Oil red O. Chondrogenesis and osteogenesis were each shown by Toluidine blue 
staining and ALP staining. Images shown are representative of independent experiments. 
 
Figure 2. Cell morphology and proliferation. (A) Phase contrast micrographs show the 
morphological changes at day 7 after culturing in the osteogenic conditions 
supplemented with Dex (D;10 nM), rhBMP-2 (B;100 ng/ml) or the combination of Dex 
and rhBMP-2 (DB). C designates the control group. Dex treatment caused hBMSCs to 
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change from an elongated shape to a cuboidal-type shape, whereas there were no 
morphological changes in cells treated with rhBMP-2. Images shown are a 
representative of all experiments. (B) Effect of Dex or rhBMP-2 on cell proliferation 
(n=4) was measured using cell proliferation reagent WST-8 at day 7 after culturing in 
DMEM supplemented with either Dex (10 nM), rhBMP-2 (100 ng/ml), or a 
combination of rhBMP-2 and Dex. Proliferation in the Dex alone or in the co-treated 
group (Dex and rhBMP-2) decreased to 70% of that seen in the control group. 
*Significantly different from the control, p<0.05.  
 
Figure 3. Alkaline phosphatase (ALP) activity of hBMSCs (n=16). (A) ALP activity 
(nmole/min/mg protein) was measured at day 7 after culturing second passaged 
hBMSCs in osteogenic differentiation medium supplemented with Dex (10nM), 
rhBMP-2 (100 ng/ml), or a combination of Dex and rhBMP-2 without pre-treatment 
with Dex. ALP activity of each treatment is presented as the mean ± SEM for individual 
hBMSCs with triplicate measurements. ALP activity was assessed by ALP staining 
after 12 days of culture. Significantly different from the control, p**<0.01, p†<0.001. 
ALP activity was analyzed according to the gender (B) and age (C) of the donors.  
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Figure 4. Osteogenic gene expression measured by RT-PCR and real-time RT-PCR. (A) 
RT-PCR analysis was performed for osteoblast-related markers, ALP, Osteopontin 
(OPN), type I collagen (Col I), and osteocalcin (OC) in addition to the osteogenesis 
promoting cytokines IGF-1 and BMP-2 after day 7 cultures grown in the same 
conditions as cultures used in the ALP activity assay. Images shown are representative 
of three independent experiments. (B) Statistical analysis of ALP, OPN, osteopontin,
and IGF-1 mRNA expression was performed on days 3 and 7 using real-time RT-PCR. 
Fold differences for each gene were calculated for each treatment group using a 
normalized CT value for the housekeeping gene, -actin, according to the 
manufacturer’s instructions. Statistical significance from the control on day 7, *p<0.05,
**p<0.01, and p<0.001. (C) The levels of cbfa1, osterix, and dlx5 mRNA expression 
were examined after 3 days and 7 days of treatment in the same condition as in (A). 
Statistical significance from the control of day 3, ዊ�p<0.01. Statistical significance from 
the control on day 7, *p<0.05, **p<0.01, and p<0.001.
Figure 5. The expression and cellular localization of Cbfa1 after treatment with BMP-2 
or Dex. (A) Immunofluorescence and DAPI staining were performed to detect Cbfa1 at 
2 and 24 hours after culturing with Dex (10 nM) or rhBMP-2 (100 ng/ml) after 
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pretreatment with serum-free DMEM for 2 hours. Fluorescence micrographs of stained 
cells show nuclei of cells (DAPI), cbfa1 expression (Cbfa1) and the merged image 
(Merged). (B) The percentage of cbfa1-positive cells was determined by calculating 
cbfa1-positive cells per DAPI-positive cells from 3 specimens for each condition after a 
time course of 2 and 24 hrs post-treatment. Statistically significant difference between 
the two groups, ዊ�ዊ�p<0.01. 
 
Figure 6. Terminal differentiation of hBMSCs. (A) hBMSCs were cultured in 
osteogenic culture medium without (C;control) or with Dex (D, 10 nM), rhBMP-2 (B, 
100 ng/ml) or 1,25 – dihydroxyvitaminD (VtD, 10 nM). OC gene expression was 
examined by both RT-PCR at day 7 and ELISA at day 21 after continuous treatments 
with each supplement. The amounts of secreted OC are presented as a fold-change 
normalized to the control.  There was a significant increase only in the culture 
condition supplemented by VtD (ዊ�p<0.01). (B) Calcium deposition was visualized by 
Alizarin red S staining after 21 days culture. Matrix mineralization was quantified by 
image analysis (C) of four representative 1.25x fields for each treatment using Spot 
software and visualized (D) by von Kossa staining at day 28. hBMSCs were treated 
with increasing doses of rhBMP-2 ranging from 100 ng/ml to 300 ng/ml. Non-treated 
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hBMSCs were void of any stained regions. rhBMP-2 treatment produced weak stains in 
some samples (Sample 1 and 5) and usually did not induce mineralization, 
independently of the treatment dose. Dex or Dex–rhBMP-2 treatment developed 
densely mineralized regions and intensive staining. *Statistical significance from the 
control, p<0.05, and **p<0.001.
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Figure 1. Characterization and multilineage differentiation of hBMSCs. (A) Stromal cells 
were cultured after Ficoll density gradient fractionation. A single cell appeared at days 2–
4 and formed fibroblastic colonies at days 10–12 after the first plating. (B) Homogeneity 
of the isolation procedure was demonstrated by FACS. Data shown were obtained from 
hBMSCs at first passage using FITC-conjugated antihuman CD105, human CD90 antibody 
as positive stem cell marker, and human CD45 antibody as negative marker. (C) Isolated 
hBMSCs were tested for the ability to differentiate in vitro to multiple lineages. Cultured 
cells were each shown to differentiate appropriately to the adipogenic (Adipo), 
chondrogenic (Chondro), and osteogenic (Osteo) lineages. Adipogenesis was indicated by 
the accumulation of neutral lipid vacuoles that stain with Oil red O. Chondrogenesis and 
osteogenesis were each shown by Toluidine blue staining and ALP staining. Images 
shown are representative of independent experiments. 
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Figure 2. Cell morphology and proliferation. (A) Phase contrast micrographs show the 
morphological changes at day 7 after culturing in the osteogenic conditions supplemented 
with Dex (D;10 nM), rhBMP-2 (B;100 ng/ml) or the combination of Dex and rhBMP-2 
(DB). C designates the control group. Dex treatment caused hBMSCs to change from an 
elongated shape to a cuboidal-type shape, whereas there were no morphological changes 
in cells treated with rhBMP-2. Images shown are a representative of all experiments. (B) 
Effect of Dex or rhBMP-2 on cell proliferation (n=4) was measured using cell proliferation 
reagent WST-8 at day 7 after culturing in DMEM supplemented with either Dex (10 nM), 
rhBMP-2 (100 ng/ml), or a combination of rhBMP-2 and Dex. Proliferation in the Dex 
alone or in the co-treated group (Dex and rhBMP-2) decreased to 70% of that seen in the 
control group. *Significantly different from the control, p<0.05.  
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Figure 3. Alkaline phosphatase (ALP) activity of hBMSCs (n=16). (A) ALP activity 
(nmole/min/mg protein) was measured at day 7 after culturing second passaged hBMSCs 
in osteogenic differentiation medium supplemented with Dex (10nM), rhBMP-2 (100 
ng/ml), or a combination of Dex and rhBMP-2 without pre-treatment with Dex. ALP 
activity of each treatment is presented as the mean ± SEM for individual hBMSCs with 
triplicate measurements. ALP activity was assessed by ALP staining after 12 days of 
culture. Significantly different from the control, p**<0.01, p¢Ó<0.001. ALP activity was 
analyzed according to the gender (B) and age (C) of the donors.  
190x254mm (300 x 300 DPI)  
 
Page 45 of 46 Development Growth and Differentiation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Figure 4. Osteogenic gene expression measured by RT-PCR and real-time RT-PCR. (A) RT-
PCR analysis was performed for osteoblast-related markers, ALP, Osteopontin (OPN), 
type I collagen (Col I), and osteocalcin (OC) in addition to the osteogenesis promoting 
cytokines IGF-1 and BMP-2 after day 7 cultures grown in the same conditions as cultures 
used in the ALP activity assay. Images shown are representative of three independent 
experiments. (B) Statistical analysis of ALP, OPN, osteopontin, and IGF-1 mRNA 
expression was performed on days 3 and 7 using real-time RT-PCR. Fold differences for 
each gene were calculated for each treatment group using a normalized CT value for the 
housekeeping gene, -actin, according to the manufacturer¡Fs instructions. Statistical 
significance from the control on day 7, *p<0.05, **p<0.01, and p<0.001. (C) The levels 
of cbfa1, osterix, and dlx5 mRNA expression were examined after 3 days and 7 days of 
treatment in the same condition as in (A). Statistical significance from the control of day 
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3, ¢Óp<0.01. Statistical significance from the control on day 7, *p<0.05, **p<0.01, and 
p<0.001.  
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Figure 5. The expression and cellular localization of Cbfa1 after treatment with BMP-2 or 
Dex. (A) Immunofluorescence and DAPI staining were performed to detect Cbfa1 at 2 and 
24 hours after culturing with Dex (10 nM) or rhBMP-2 (100 ng/ml) after pretreatment 
with serum-free DMEM for 2 hours. Fluorescence micrographs of stained cells show nuclei 
of cells (DAPI), cbfa1 expression (Cbfa1) and the merged image (Merged). (B) The 
percentage of cbfa1-positive cells was determined by calculating cbfa1-positive cells per 
DAPI-positive cells from 3 specimens for each condition after a time course of 2 and 24 
hrs post-treatment. Statistically significant difference between the two groups, 
**p<0.01. 
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Figure 6. Terminal differentiation of hBMSCs. (A) hBMSCs were cultured in osteogenic 
culture medium without (C;control) or with Dex (D, 10 nM), rhBMP-2 (B, 100 ng/ml) or 
1,25 – dihydroxyvitaminD (VtD, 10 nM). OC gene expression was examined by both RT-
PCR at day 7 and ELISA at day 21 after continuous treatments with each supplement. The 
amounts of secreted OC are presented as a fold-change normalized to the control. There 
was a significant increase only in the culture condition supplemented by VtD (*p<0.01). 
(B) Calcium deposition was visualized by Alizarin red S staining after 21 days culture. 
Matrix mineralization was quantified by image analysis (C) of four representative 1.25x 
fields for each treatment using Spot software and visualized (D) by von Kossa staining at 
day 28. hBMSCs were treated with increasing doses of rhBMP-2 ranging from 100 ng/ml 
to 300 ng/ml. Non-treated hBMSCs were void of any stained regions. rhBMP-2 treatment 
produced weak stains in some samples (Sample 1 and 5) and usually did not induce 
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mineralization, independently of the treatment dose. Dex or Dex–rhBMP-2 treatment 
developed densely mineralized regions and intensive staining. *Statistical significance 
from the control, p<0.05, and **p<0.001. 
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